GENE News Alert Genetic Technologies Ltd (GENE) 0.36 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Genetic Technologies Ltd (GENE) 0.36 $GENE

Clinical Validation Study Supporting the Use of BREVAGenplus(R) in Breast Cancer Risk Assessment
Marketwired - Wed Dec 17, 4:30AM CST
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company" announces that findings from a new research study show that adding a panel of 77 single-nucleotide polymorphisms ("SNPs" improves the predictive accuracy of four commonly used breast cancer risk assessment models. This same panel of 77 SNPs is used in the Company's recently released BREVAGenplus(R), an easy-to-use predictive risk test for sporadic, or non-hereditary, breast cancer. Results were presented at the 2014 San Antonio Breast Cancer Symposium, on December 13, 2014.
GENE: 0.36 (+0.02)

PHENOGEN SCIENCES, INC. ANNOUNCES CLINICAL VALIDATION STUDY SUPPORTING THE USE OF BREVAGENPLUS(R) IN BREAST CANCER RISK ASSESSMENT
GlobeNewswire - Tue Dec 16, 10:23AM CST
Phenogen Sciences, Inc. (www.phenogensciences.com) announces that findings from a new research study show that adding a panel of 77 single-nucleotide polymorphisms (SNPs) improves the predictive accuracy of four commonly-used breast cancer risk assessment models. This same panel of 77 SNPs is used in Phenogen Sciences' recently released BREVAGenplus(R), an easy-to-use predictive risk test for sporadic, or non-hereditary, breast cancer. Results were presented at the 2014 San Antonio Breast Cancer Symposium on December 13, 2014.
GENE: 0.36 (+0.02)

Genetic Technologies Announces Quarterly BREVAGen(TM) Results
Marketwire - Mon Oct 06, 4:42AM CDT
Molecular diagnostics (MDx) company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company" reported 942 BREVAGen(TM) test samples received in the September Quarter 2014, ahead of the release of the second generation breast cancer risk assessment test, BREVAGenplus(R), in October 2014.
GENE: 0.36 (+0.02)

Genetic Technologies Launches BREVAGenplus(R) Breast Cancer Risk Assessment Test
Marketwire - Wed Oct 01, 4:30AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company" ) is pleased to announce the US launch of BREVAGenplus, an easy-to-use predictive risk test for the millions of women at risk of developing sporadic, or non-hereditary, breast cancer. The test is an enhancement of the Company's first generation product, BREVAGen(TM). BREVAGenplus assesses both clinical risk factors and genetic markers known to be associated with sporadic, or non-hereditary, breast cancer to determine a woman's five-year and lifetime risk of developing the disease. It is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans. The test is directed towards Caucasian, Hispanic and African-American women, age 35 years or above, who have not had breast cancer, lobular carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS), and have one or more risk factors for developing breast cancer.
GENE: 0.36 (+0.02)

Genetic Technologies Announces Appointment of Independent Non-Executive Directors
Marketwire - Wed Sep 24, 4:30AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company" is pleased to advise that Mr. David Carter and Dr. Lindsay Wakefield have today been appointed Non-Executive Directors of the Company on "casual appointment", in that the new appointees will then be required to submit themselves for re-election at the upcoming AGM, as per article 19.4 of the Company's Constitution. The initial Director's interest notice - Appendix 3X, on behalf of Mr. Carter and Dr. Wakefield are attached.
GENE: 0.36 (+0.02)

Genetic Technologies Announces Divestment of Australian Based Heritage Business
Marketwire - Mon Sep 22, 4:30AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company" ) is pleased to announce that it has signed a binding contract of sale for its heritage Australian Genetics business ("Australian Genetics" to Specialist Diagnostics Services Ltd ("SDS" , the wholly owned pathology subsidiary of Primary Health Care Ltd. The Australian Genetics business provides diagnostic and sequencing services encompassing Australia-only medical, forensic, paternity and animal genomic testing. Under the terms of sale, SDS will acquire the Australian Genetics business for $2,000,000 in cash. Assuming all conditions are met, settlement of the transaction is expected to occur within the next month.
GENE: 0.36 (+0.02)

Transformational Restructuring Plans to Support Molecular Diagnostics Focus and Finalisation of Financing
Marketwire - Mon Sep 15, 4:30AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company" is pleased to announce plans for the restructure and realignment of group activities. These changes will enable the Company to focus its strategy on the US molecular diagnostics ("MDx" market and commercialisation of the Company's lead breast cancer risk test BREVAGen(TM). The restructure and realignment of group activities follows a recent review of operations by the Company aimed at supporting the Company's US MDx strategy. The core plans approved by the Board include:
GENE: 0.36 (+0.02)

Genetic Technologies Announces Further Patent Success in USA
Marketwire - Tue Aug 26, 4:30AM CDT
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce that the United States District Court for the Middle District of North Carolina last week issued an Order denying a motion brought by GlaxoSmithKline, LLC (GSK) to dismiss the patent infringement law suit brought against it by GTG.
GENE: 0.36 (+0.02)

Why Genetic Technologies (GENE) Stock Is Spiking Today
at The Street - Mon Jul 07, 1:31PM CDT
Gene Technologies (GENE) shares are climbing after reporting a rise in sales of its cheek swab breast caner test, BREVAGen.
GENE: 0.36 (+0.02)

Genetic Technologies Provides BREVAGen(TM) Revenue Update for Quarter Ending June 30, 2014
Marketwire - Mon Jul 07, 4:30AM CDT
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce that the number of BREVAGen(TM) test samples received during the quarter ended June 30, 2014 returned to levels achieved in late CY13. Total patient samples received during the quarter were 1,096, representing 37% growth over the March 2014 quarter (800 samples).
GENE: 0.36 (+0.02)

Genetic Technologies Announces Update on Intellectual Property
Marketwire - Wed Feb 12, 11:26AM CST
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) today announced that it received a further ExParte Re-Examination Certificate from the United States Patent and Trademark Office ("USPTO" , dated February 10, 2014 (the "Certificate" . The Certificate follows the third request for ex parte re-examination of claims 1-15, 17,18, 26-29 and 32 of the Company's U.S. Patent No. 5,612,179 (the '179 patent) by Merial L.L.C. of Duluth, Georgia, as announced by the Company on September 30, 2013.
GENE: 0.36 (+0.02)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 109

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
Payoneer Gets OCC Nod, but the Finish Line Is Ahead

Updated Category News Views 121

Federal bank paperwork is not usually thrilling, yet Payoneer just found a potentially meaningful lever for its cross-border payments machine. The company received preliminary conditional approval from the Office of the Comptroller of the Currency to form PAYO Digital Bank, a national trust bank intended to support stablecoin services. That is a real regulatory milestone...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 29

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 91

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 69

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 83

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 130

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 313

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Pinnacol’s Community Work Earns Denver Chamber Recognition

Updated Category News Views 67

A workers’ comp insurer usually becomes visible on somebody’s worst day; Pinnacol Assurance is being recognized for the work it keeps doing around those days. The Denver Metro Chamber of Commerce has given the Colorado-based, member-owned carrier its 2026 Business Impact Award for Corporate Social Responsibility. Awards can be cheap applause, frankly. This one...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming Lives with Sober.Buzz: Embrace the $BUZZ Journey

Updated Category News Views 568

Welcome to Sober.Buzz and the Journey of Transformation Sober.Buzz introduces the Sober Token, known for its symbol $BUZZ, representing a promising initiative aimed at creating a supportive and empowering global community for individuals in recovery from addiction. Designed by those who understand the struggles, the project offers hope and encouragement for those seeking...

Continue Reading
Revolutionizing Ecommerce with Artifi's AI Product Setup Tool

Updated Category News Views 188

Introduction to Artifi's New AI Feature Artifi, a dynamic player in SaaS solutions for product customization, has announced a groundbreaking new feature known as AI Automated Product Setup. This innovative tool aims to drastically reduce setup times, allowing suppliers to efficiently prepare their product data for ecommerce platforms. Understanding the Setup Process The...

Continue Reading
Cleeng Pro: Revolutionizing D2C Subscription Management Today

Updated Category News Views 180

Cleeng Pro: An Innovative Platform for D2C Subscriptions Cleeng, a leader in Subscriber Retention Management, has recently introduced Cleeng Pro, a groundbreaking direct-to-consumer (D2C) subscription platform. This platform empowers creators, developers, and entrepreneurs to establish their subscription services with remarkable efficiency, all without any cost for their...

Continue Reading
SciBase's Nevisense Device Sold to NIH: A New Era in Dermatology

Updated Category News Views 255

SciBase Holding AB hit the headlines back in 2024 when it announced the sale of its flagship device, Nevisense, to the National Institutes of Health (NIH). Traders were buzzing, not just because SciBase is known for its cutting-edge dermatology tech, but because this sale signaled a massive leap into uncharted territory regarding skin health. The NIH isn't just any buyer;...

Continue Reading
FLUENT Launches Innovative MOODS Black in the Sunshine State

Updated Category News Views 262

FLUENT Launches Innovative MOODS Black in the Sunshine State FLUENT Corp. (CSE: FNT.U) (OTCQB: CNTMF), a leading national cannabis company, is thrilled to announce the exciting launch of its latest product, MOODS Black. This new addition to the well-regarded MOODS lineup showcases high-potency cannabis oil infused with cannabis-derived terpenes, ensuring a superior and...

Continue Reading